• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

胆管癌肿瘤微环境及其对抗肿瘤免疫的影响:新型治疗方法的未来展望。

Tumor Microenvironment and its Implications for Antitumor Immunity in Cholangiocarcinoma: Future Perspectives for Novel Therapies.

机构信息

Hepatobiliary/Liver Transplantation Center, The First Affiliated Hospital of Nanjing Medical University, Key Laboratory of Living Donor Transplantation, Chinese Academy of Medical Sciences, Nanjing, Jiangsu, China.

Stomatological college of Nanjing Medical University, Nanjing, Jiangsu, China.

出版信息

Int J Biol Sci. 2022 Aug 21;18(14):5369-5390. doi: 10.7150/ijbs.73949. eCollection 2022.

DOI:10.7150/ijbs.73949
PMID:36147461
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9461676/
Abstract

The incidence of cholangiocarcinoma (CCA) has been increasing over the past few years. Although there are surgery, chemotherapy and other conventional treatment methods, the effect is not as expected. At present, immunotherapy has become the research frontier of cancer treatment, and CCA tumor microenvironment (TME) is becoming a hot exploration direction of immunobiology. TME can affect tumor progression through changes in metabolism, secretion and immunity. Accordingly, understanding the role played by immune cells and stromal cells in TME is important for the study of CCA immunotherapy. This review will discuss the interactions between immune cells (including CD8 T cells, CD4 T cells, macrophages, natural killer cells, dendritic cells, myeloid suppressor cells, mast cells, and neutrophils) and stromal cells (including cancer-associated fibroblasts, endothelial cells) in the TME of CCA. In addition, we will also discuss current research results on TME of CCA and recent advances in immunotherapy.

摘要

近年来,胆管癌(CCA)的发病率一直在上升。尽管有手术、化疗和其他常规治疗方法,但效果并不如预期。目前,免疫疗法已成为癌症治疗的研究前沿,CCA 肿瘤微环境(TME)正成为免疫生物学的热门探索方向。TME 可通过代谢、分泌和免疫的变化影响肿瘤进展。因此,了解免疫细胞和基质细胞在 TME 中所起的作用对于 CCA 免疫治疗的研究非常重要。这篇综述将讨论免疫细胞(包括 CD8 T 细胞、CD4 T 细胞、巨噬细胞、自然杀伤细胞、树突状细胞、髓源性抑制细胞、肥大细胞和中性粒细胞)和基质细胞(包括癌相关成纤维细胞、内皮细胞)在 CCA 的 TME 中的相互作用。此外,我们还将讨论 CCA 的 TME 目前的研究结果和免疫治疗的最新进展。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e5b7/9461676/65a989c75ae8/ijbsv18p5369g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e5b7/9461676/ba0ec4d85a7e/ijbsv18p5369g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e5b7/9461676/413e08c57c5d/ijbsv18p5369g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e5b7/9461676/422a0144bce6/ijbsv18p5369g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e5b7/9461676/80126b2160d8/ijbsv18p5369g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e5b7/9461676/cae1c299bd22/ijbsv18p5369g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e5b7/9461676/65a989c75ae8/ijbsv18p5369g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e5b7/9461676/ba0ec4d85a7e/ijbsv18p5369g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e5b7/9461676/413e08c57c5d/ijbsv18p5369g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e5b7/9461676/422a0144bce6/ijbsv18p5369g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e5b7/9461676/80126b2160d8/ijbsv18p5369g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e5b7/9461676/cae1c299bd22/ijbsv18p5369g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e5b7/9461676/65a989c75ae8/ijbsv18p5369g006.jpg

相似文献

1
Tumor Microenvironment and its Implications for Antitumor Immunity in Cholangiocarcinoma: Future Perspectives for Novel Therapies.胆管癌肿瘤微环境及其对抗肿瘤免疫的影响:新型治疗方法的未来展望。
Int J Biol Sci. 2022 Aug 21;18(14):5369-5390. doi: 10.7150/ijbs.73949. eCollection 2022.
2
The role of tumor-infiltrating lymphocytes in cholangiocarcinoma.肿瘤浸润淋巴细胞在胆管癌中的作用。
J Exp Clin Cancer Res. 2022 Apr 7;41(1):127. doi: 10.1186/s13046-022-02340-2.
3
Tumor immune microenvironment and the current immunotherapy of cholangiocarcinoma (Review).肿瘤免疫微环境与胆管癌的当前免疫治疗(综述)。
Int J Oncol. 2023 Dec;63(6). doi: 10.3892/ijo.2023.5585. Epub 2023 Oct 27.
4
The immune milieu of cholangiocarcinoma: From molecular pathogenesis to precision medicine.胆管癌的免疫微环境:从分子发病机制到精准医学。
J Autoimmun. 2019 Jun;100:17-26. doi: 10.1016/j.jaut.2019.03.007. Epub 2019 Mar 9.
5
Cholangiocarcinoma: what are the most valuable therapeutic targets - cancer-associated fibroblasts, immune cells, or beyond T cells?胆管癌:最有价值的治疗靶点是什么——癌相关成纤维细胞、免疫细胞,还是 T 细胞以外的细胞?
Expert Opin Ther Targets. 2021 Oct;25(10):835-845. doi: 10.1080/14728222.2021.2010046. Epub 2021 Dec 3.
6
The role of tumour microenvironment: a new vision for cholangiocarcinoma.肿瘤微环境的作用:胆管癌的新视角。
J Cell Mol Med. 2019 Jan;23(1):59-69. doi: 10.1111/jcmm.13953. Epub 2018 Nov 5.
7
Impact of microenvironment and stem-like plasticity in cholangiocarcinoma: molecular networks and biological concepts.胆管癌中微环境和干细胞样可塑性的影响:分子网络和生物学概念。
J Hepatol. 2015 Jan;62(1):198-207. doi: 10.1016/j.jhep.2014.09.007. Epub 2014 Sep 16.
8
Cancer-Associated Fibroblasts and Extracellular Matrix: Therapeutical Strategies for Modulating the Cholangiocarcinoma Microenvironment.癌症相关成纤维细胞和细胞外基质:调节胆管癌微环境的治疗策略。
Curr Oncol. 2023 Apr 14;30(4):4185-4196. doi: 10.3390/curroncol30040319.
9
The Functional Roles of Immune Cells in Primary Liver Cancer.免疫细胞在原发性肝癌中的功能作用
Am J Pathol. 2022 Jun;192(6):826-836. doi: 10.1016/j.ajpath.2022.02.004. Epub 2022 Mar 23.
10
Targeting the tumor microenvironment in cholangiocarcinoma: implications for therapy.靶向胆管癌的肿瘤微环境:对治疗的意义
Expert Opin Ther Targets. 2021 Feb;25(2):153-162. doi: 10.1080/14728222.2021.1882998. Epub 2021 Feb 7.

引用本文的文献

1
Blood-Based Biomarkers as Predictive and Prognostic Factors in Immunotherapy-Treated Patients with Solid Tumors-Currents and Perspectives.血液生物标志物作为实体瘤免疫治疗患者的预测和预后因素——现状与展望
Cancers (Basel). 2025 Jun 16;17(12):2001. doi: 10.3390/cancers17122001.
2
Factors Contributing to the High Malignancy Level of Cholangiocarcinoma and Its Epidemiology: Literature Review and Data.胆管癌高恶性程度的相关因素及其流行病学:文献综述与数据
Biology (Basel). 2025 Mar 28;14(4):351. doi: 10.3390/biology14040351.
3
Research progress of T cells in cholangiocarcinoma.

本文引用的文献

1
Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial.卡瑞利珠单抗联合阿帕替尼用于可切除肝细胞癌围手术期治疗的有效性和安全性:一项单臂、开放标签、Ⅱ期临床研究。
J Immunother Cancer. 2022 Apr;10(4). doi: 10.1136/jitc-2022-004656.
2
A Phase II Study of Pembrolizumab in Combination with Capecitabine and Oxaliplatin with Molecular Profiling in Patients with Advanced Biliary Tract Carcinoma.帕博利珠单抗联合卡培他滨和奥沙利铂用于晚期胆管癌患者的分子特征分析的 II 期研究。
Oncologist. 2022 Mar 11;27(3):e273-e285. doi: 10.1093/oncolo/oyab073.
3
胆管癌中T细胞的研究进展
Front Immunol. 2025 Feb 25;16:1453344. doi: 10.3389/fimmu.2025.1453344. eCollection 2025.
4
Infiltrating T lymphocytes and tumor microenvironment within cholangiocarcinoma: immune heterogeneity, intercellular communication, immune checkpoints.胆管癌中的浸润性T淋巴细胞与肿瘤微环境:免疫异质性、细胞间通讯、免疫检查点
Front Immunol. 2025 Jan 8;15:1482291. doi: 10.3389/fimmu.2024.1482291. eCollection 2024.
5
Advancing Cholangiocarcinoma Care: Insights and Innovations in T Cell Therapy.推进胆管癌治疗:T细胞疗法的见解与创新
Cancers (Basel). 2024 Sep 23;16(18):3232. doi: 10.3390/cancers16183232.
6
Focusing on the Immune Cells: Recent Advances in Immunotherapy for Biliary Tract Cancer.聚焦免疫细胞:胆管癌免疫治疗的最新进展
Cancer Manag Res. 2024 Jul 29;16:941-963. doi: 10.2147/CMAR.S474348. eCollection 2024.
7
Recent Advances in Immunotherapy for Advanced Biliary Tract Cancer.免疫治疗在晚期胆道癌中的最新进展。
Curr Treat Options Oncol. 2024 Aug;25(8):1089-1111. doi: 10.1007/s11864-024-01243-y. Epub 2024 Jul 27.
8
Causal relationship between immune cell phenotypes and risk of biliary tract cancer: evidence from Mendelian randomization analysis.免疫细胞表型与胆道癌风险的因果关系:来自孟德尔随机分析的证据。
Front Immunol. 2024 Jul 10;15:1430551. doi: 10.3389/fimmu.2024.1430551. eCollection 2024.
9
An anoikis-related gene signature predicts prognosis, drug sensitivity, and immune microenvironment in cholangiocarcinoma.一种与失巢凋亡相关的基因特征可预测胆管癌的预后、药物敏感性和免疫微环境。
Heliyon. 2024 Jun 3;10(11):e32337. doi: 10.1016/j.heliyon.2024.e32337. eCollection 2024 Jun 15.
10
MAL2 reprograms lipid metabolism in intrahepatic cholangiocarcinoma via EGFR/SREBP-1 pathway based on single-cell RNA sequencing.基于单细胞 RNA 测序,MAL2 通过 EGFR/SREBP-1 通路重编程肝内胆管癌中的脂质代谢。
Cell Death Dis. 2024 Jun 12;15(6):411. doi: 10.1038/s41419-024-06775-7.
Tumor-derived exosomes induce immunosuppressive macrophages to foster intrahepatic cholangiocarcinoma progression.
肿瘤来源的外泌体诱导免疫抑制性巨噬细胞促进肝内胆管癌进展。
Hepatology. 2022 Oct;76(4):982-999. doi: 10.1002/hep.32387. Epub 2022 Feb 28.
4
Tumor-associated macrophages promote cholangiocarcinoma progression via exosomal Circ_0020256.肿瘤相关巨噬细胞通过外泌体 Circ_0020256 促进胆管癌进展。
Cell Death Dis. 2022 Jan 28;13(1):94. doi: 10.1038/s41419-022-04534-0.
5
Macrophages-aPKC-CCL5 Feedback Loop Modulates the Progression and Chemoresistance in Cholangiocarcinoma.巨噬细胞-aPKC-CCL5 反馈环调节胆管癌的进展和化疗耐药性。
J Exp Clin Cancer Res. 2022 Jan 15;41(1):23. doi: 10.1186/s13046-021-02235-8.
6
MiR-206 suppresses the deterioration of intrahepatic cholangiocarcinoma and promotes sensitivity to chemotherapy by inhibiting interactions with stromal CAFs.miR-206 通过抑制与基质 CAFs 的相互作用来抑制肝内胆管癌的恶化并提高对化疗的敏感性。
Int J Biol Sci. 2022 Jan 1;18(1):43-64. doi: 10.7150/ijbs.62602. eCollection 2022.
7
Lenvatinib Plus PD-1 Inhibitors as First-Line Treatment in Patients With Unresectable Biliary Tract Cancer: A Single-Arm, Open-Label, Phase II Study.仑伐替尼联合PD-1抑制剂作为不可切除胆管癌患者的一线治疗:一项单臂、开放标签的II期研究。
Front Oncol. 2021 Nov 24;11:751391. doi: 10.3389/fonc.2021.751391. eCollection 2021.
8
Neoantigen-driven B cell and CD4 T follicular helper cell collaboration promotes anti-tumor CD8 T cell responses.新抗原驱动的 B 细胞和 CD4+T 滤泡辅助细胞协同作用促进抗肿瘤 CD8+T 细胞反应。
Cell. 2021 Dec 9;184(25):6101-6118.e13. doi: 10.1016/j.cell.2021.11.007. Epub 2021 Nov 30.
9
Mutant IDH Inhibits IFNγ-TET2 Signaling to Promote Immunoevasion and Tumor Maintenance in Cholangiocarcinoma.突变 IDH 抑制 IFNγ-TET2 信号通路促进胆管癌的免疫逃逸和肿瘤维持。
Cancer Discov. 2022 Mar 1;12(3):812-835. doi: 10.1158/2159-8290.CD-21-1077.
10
Distribution and density of tertiary lymphoid structures predict clinical outcome in intrahepatic cholangiocarcinoma.三级淋巴结构的分布和密度可预测肝内胆管癌的临床结局。
J Hepatol. 2022 Mar;76(3):608-618. doi: 10.1016/j.jhep.2021.10.030. Epub 2021 Nov 15.